

Earnhart & Associates

[View the current Earnhart & Associates Page on BioPortfolio.com](http://www.bioportfolio.com/biorporate/22262-Earnhart+%26+Associates.html)

(<http://www.bioportfolio.com/biorporate/22262-Earnhart+%26+Associates.html>)

Contact Details:

1000 Westbank Drive Suite 5B

Austin

Texas

78746

United States of America

Tel: 512.320.8580

Fax: 512.320.8581

Email:

Earnhart & Associates, Inc. is a healthcare consulting firm that specializes in ambulatory care services. We have been providing hi-quality, cost-effective consulting and management services for over 17 years

Recent Publications by Earnhart & Associates:



- [An octavalent lyme disease vaccine induces antibodies that recognize all incorporated OspC type-specific sequences.](#)
Lyme disease is the most common vector-borne disease in North America and... 21st June, 2008
Department of Microbiology and Immunology, Virginia Commonwealth- Hum Vaccin. 2007 Nov-Dec;3(6):281-9. Epub 2007 Jul 2.
- [OspC phylogenetic analyses support the feasibility of a broadly protective polyvalent chimeric Lyme disease vaccine.](#)
Using available Borrelia outer surface protein C (OspC) sequences, a... 15th June, 2007
Department of Microbiology and Immunology, Center for the Study of- Clin Vaccine Immunol. 2007 May;14(5):628-34. Epub 2007 Mar 14. ([DOI Direct Link](#))
- [Construction and analysis of variants of a polyvalent Lyme disease vaccine: approaches for improving the immune response to chimeric vaccinogens.](#)
There is currently no Lyme disease vaccine commercially available for use... 1st June, 2007
Department of Microbiology and Immunology, Medical College of Virginia at- Vaccine. 2007 Apr 30;25(17):3419-27. Epub 2007 Jan 17. ([DOI Direct Link](#))
- [Development of an OspC-based tetravalent, recombinant, chimeric vaccinogen that elicits bactericidal antibody against diverse Lyme disease spirochete strains.](#)
Lyme disease is the most common arthropod-borne disease in North America... 28th February, 2007
Department of Microbiology and Immunology, Medical College of Virginia at- Vaccine. 2007 Jan

- 5;25(3):466-80. Epub 2006 Aug 8. ([DOI Direct Link](#))
- [Analysis of antibody response in humans to the type A OspC loop 5 domain and assessment of the potential utility of the loop 5 epitope in Lyme disease vaccine development.](#)
*The OspC protein of Borrelia burgdorferi is an immunodominant antigen....*9th January, 2007
 Department of Microbiology and Immunology, Medical College of Virginia at- Clin Vaccine Immunol. 2006 Oct;13(10):1162-5. ([DOI Direct Link](#))
 - [Demonstration of OspC type diversity in invasive human lyme disease isolates and identification of previously uncharacterized epitopes that define the specificity of the OspC murine antibody response.](#)
*Outer surface protein C (OspC) of the Lyme disease spirochetes is an...*7th January, 2006
 Department of Microbiology and Immunology, Medical College of Virginia at- Infect Immun. 2005 Dec;73(12):7869-77. ([DOI Direct Link](#))
 - [Potential novel epitopes in the extracellular products of oyster homogenate-supplemented Perkinsus marinus cells are not detected by subtractive immunization.](#)
*The extracellular products (ECPs) of the oyster parasite Perkinsus marinus...*1st September, 2005
 Department of Environmental and Aquatic Animal Health, School of Marine- J Parasitol. 2005 Jun;91(3):689-91.
 - [Monoclonal antibody analysis of Perkinsus marinus extracellular products.](#)
*The protozoan oyster parasite Perkinsus marinus releases a complex set of...*20th July, 2005
 Department of Environmental and Aquatic Animal Health, School of Marine- Int J Parasitol. 2005 Feb;35(2):171-84. Epub 2004 Dec 19. ([DOI Direct Link](#))
 - [Supplementation of Perkinsus marinus cultures with host plasma or tissue homogenate enhances their infectivity.](#)
*The protozoan oyster parasite Perkinsus marinus can be cultured in vitro...*9th April, 2004
 Department of Environmental and Aquatic Animal Health, School of Marine- Appl Environ Microbiol. 2004 Jan;70(1):421-31.
 - [GAO report fills in picture of niche hospitals.](#)
*The protozoan oyster parasite Perkinsus marinus can be cultured in vitro...*21st February, 2004
 Earnhart &- OR Manager. 2003 Dec;19(12):26.
 - [The humoral response to in vitro generated parasite antigens is enhanced by the removal of a defined media component prior to immunization.](#)
*Concentrated culture supernatants containing the extracellular products...*31st October, 2003
 Department of Environmental and Aquatic Animal Health, School of Marine- J Immunol Methods. 2003 Jul;278(1-2):67-78.
 - [Make clear rules on block scheduling.](#)
*The protozoan oyster parasite Perkinsus marinus can be cultured in vitro...*28th October, 2003
 - OR Manager. 2003 Sep;19(9):40, 42.
 - [Host oyster tissue extracts modulate in vitro protease expression and cellular differentiation in the protozoan parasite, Perkinsus marinus.](#)
*Perkinsus marinus is responsible for a chronic disease (Dermo) of the...*12th July, 2003
 Department of Environmental and Aquatic Animal Health, School of Marine- Parasitology. 2003 Apr;126(Pt 4):293-302.
 - [What's best way to market your ASC?](#)
*Perkinsus marinus is responsible for a chronic disease (Dermo) of the...*16th May, 2003
 Earnhart &- OR Manager. 2003 Apr;19(4):28-9.

Press Releases on Earnhart & Associates:

Compressus Builds Momentum with 3 Interoperability Implementation Project Agreements	25th November, 2009	Compressus, Inc.	<p>WASHINGTON, Nov. 25 /PRNewswire/ -- Compressus, leaders in interoperability of disparate healthcare IT systems, today announced the company has recently completed three customer agreements for the</p>
Accumetrics to Present at the 21st Annual Piper Jaffray Health Care Conference	24th November, 2009	Accumetrics, Inc.	<p>SAN DIEGO, Nov. 24 /PRNewswire/ -- Accumetrics, Inc., a privately-held developer and marketer of the VerifyNow® System, the first rapid and easy-to-use diagnostic system for measuring an individual</p>
NAFG Expands Surrogacy and Egg Donation Program into Dallas	24th November, 2009	Northeast Assisted Fertility Group	<p>DALLAS, Nov. 24 /PRNewswire/ -- The Northeast Assisted Fertility Group (NAFG), already the leading surrogacy and egg donation program in Boston and New York, is pleased to announce the opening of a</p>
Wellcore to Introduce Consumer Technology Products that Promote Health and Wellness	24th November, 2009	Wellcore Corporation	<p>SAN JOSE, Calif., Nov. 24 /PRNewswire/ -- Wellcore Corporation, a Silicon Valley-based company dedicated to developing wireless products and services that promote wellness, safety and security, is</p>
Reportlinker Adds Fluoroscopy and Mobile C-Arms - Global Market Opportunities	23rd November, 2009	Reportlinker	<p>NEW YORK, Nov. 23 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Fluoroscopy and Mobile C-Arms - Global Market Opportunities http://www</p>

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

